Healthcare Sales & Marketing Network News: ritonavir

Searching News Database: ritonavir

HSMN NewsFeed - 17 Dec 2019
Prasco launches NuvaRing(R) (etonogestrel/ethinyl estradiol vaginal ring) Authorized Generic in the United States
Biopharmaceuticals Generics Drug Delivery Product Launch

HSMN NewsFeed - 20 Aug 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology

HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
Biopharmaceuticals FDA Licensing

HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 19 May 2017
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Sep 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jul 2016
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Apr 2016
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
Biopharmaceuticals

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Sep 2015
AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Apr 2014
Gilead�s Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals

HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 8 Jan 2014
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 12 Dec 2013
VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia
Biopharmaceuticals Licensing

HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead�s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Nov 2013
Merck�s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology

HSMN NewsFeed - 26 Jun 2013
VIVUS Announces SPEDRA (avanafil) Approval in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 16 Jan 2013
European Commission Approves PREZISTA(R) (darunavir) 800 mg Tablet Once a Day Reducing the Number of Pills Taken by People Living With HIV
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Feb 2011
Covidien Receives FDA Approval for Fentanyl Transdermal System Patch
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 29 Sep 2010
Tobira Therapeutics Inc. Raises $31 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 3 Sep 2010
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology

HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 29 Jan 2010
Teva UK Limited Launches Lercanidipine Hydrochloride Film-Coated Tablets
Biopharmaceuticals Generics

HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 20 Nov 2009
FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Sep 2009
European Union Commission Approves Expanded Use of ISENTRESS(R) (raltegravir), from MSD, in Adult Patients with HIV-1 Infection
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals

HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Mar 2009
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Biopharmaceuticals Generics FDA HIV/AIDS

HSMN NewsFeed - 19 Feb 2009
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Feb 2009
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
Biopharmaceuticals

HSMN NewsFeed - 27 Nov 2008
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 18 Nov 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 29 Aug 2008
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals

HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Aug 2008
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Biopharmaceuticals HIV/AIDS Distribution

HSMN NewsFeed - 24 Jun 2008
European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Na�ve HIV-1 Infected Adults
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Apr 2008
European Commission Approves Viread(R) for Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 7 Feb 2008
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals FDA HIV/AIDS

HSMN NewsFeed - 18 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 21 Dec 2007
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 21 Dec 2007
ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 11 Dec 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 10 Dec 2007
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Biopharmaceuticals

HSMN NewsFeed - 4 Dec 2007
Myriad Genetics Submits IND on Vivecon
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Nov 2007
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology

HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 2 Nov 2007
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2007
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 17 Oct 2007
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 15 Oct 2007
UPDATE: FDA Approves ISENTRESS(TM) (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Sep 2007
ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 17 Sep 2007
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Jul 2007
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Jul 2007
TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 27 Jun 2007
FDA Priority Review Granted for ISENTRESS(TM) (raltegravir), Merck's Investigational Integrase Inhibitor for HIV
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 25 Jun 2007
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Jun 2007
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 17 May 2007
Health Canada approves REYATAZ(R) (atazanavir sulfate) 300 mg single capsule formulation in combination therapy for adults with HIV-1 infection
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Mar 2007
Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 16 Feb 2007
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
Biopharmacetuicals HIV/AIDS

HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Biopharmaceuticals

HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Dec 2006
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 13 Nov 2006
Interim Analysis of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 3 Nov 2006
Newly-Published Data Showed LEVITRA(R) Treated Erectile Dysfunction Effectively at First Dose In Men With Certain Associated Cardiovascular Conditions
Biopharmaceuticals

HSMN NewsFeed - 20 Oct 2006
FDA Approves REYATAZ(R) (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 12 Oct 2006
Ambrilia Biopharma and Merck & Co., Inc. Sign Licensing Agreement Granting Merck Worldwide Rights to Ambrilia's HIV/AIDS Protease Inhibitor Program
Biopharmaceuticals Licensing HIV/AIDS

HSMN NewsFeed - 9 Oct 2006
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 2 Oct 2006
Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 17 Aug 2006
Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra(R) Presented at IAC 2006 and Published in The Lancet
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 14 Aug 2006
96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS

HSMN NewsFeed - 3 Jul 2006
Abbott's New Tablet Formulation of Kaletra(R) (lopinavir/ritonavir) Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Jun 2006
New Data Show FUZEON(R) Continues to Provide Significant Immune System Benefits in Patients Despite Ongoing Viral Replication
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 23 May 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 16 May 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Apr 2006
Abbott's New Tablet Formulation of Kaletra(R) (Lopinavir/Ritonavir) Receives Positive Opinion From the European Medicines Agency
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 27 Apr 2006
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 22 Mar 2006
Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure
Biopharmaceuticals

HSMN NewsFeed - 8 Mar 2006
U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R)
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 6 Mar 2006
Tibotec Announces FDA Acceptance for Review of NDA for TMC114
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 10 Feb 2006
Schering-Plough Presents Vicriviroc Clinical Study Results at 13th Conference on Retroviruses and Opportunistic Infections
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 9 Feb 2006
Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2006
Roche to Focus Resources on Availability of INVIRASE(R), Now Preferred Formulation of Saquinavir
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Jan 2006
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 17 Jan 2006
Roche and Trimeris Announce Selection of Two Next Generation HIV Fusion Inhibitor Drug Candidates for Development
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 9 Jan 2006
Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 9 Jan 2006
Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate)
Biopharmaceuticals HIV/AIDS

Return to NewsFeed

Additional items found! 72

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 72 additional stories matching:
ritonavir
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.